Loading...

AVDL AVADEL PHARMACEUTICALS PLC US FDA Inspections 8-K Filing

VDL

VDL

AVADEL PHARMACEUTICALS PLC

(AVDL)

2024 8-K

Acquisition Update

Acquisition Update

Acquisition Announcement

Acquisition Announcement

Financial Results Update

Company Acquisition

Settlement Agreement

Royalty Payment Updates

Exclusive License Agreement

Financial Statements

Regulatory Compliance

Pre-Market Approval

Financial Statements

Regulatory Compliance

Investor Update

Financial Results

Financial Update

Management Change

Financial Results

Court Ruling Favorable

FDA Review Update

Financial Results Announcement

Annual Meeting of Shareholders

Index Inclusion

Appointment of Director

Open Market Sale Agreement

Financial Results Announcement

Termination of ADR Program

Appeal of Patent Lawsuit

Financial Results Announcement

Financial Results

Financial Results Announcement

Financial Results Announcement

Disinvestment of Assets

Amendment Approval at Annua...

Exchange of Senior Notes

Financial Results Announcement

FDA Approval of LUMRYZ for ...

Senior Notes Exchange

Offering Closed

Underwriting Agreement for ...

Financial Results and Excha...

Exchange Agreements

FDA Authorization for Impor...

FDA Approval Amendment

Repayment of Senior Notes

External Links:

Avadel Pharmaceuticals confirmed that the FDA is still reviewing its Supplemental New Drug Application for LUMRYZ, aimed at treating narcolepsy in pediatric patients, with a target action date of September 7, 2024.

AI Assistant

AVADEL PHARMACEUTICALS PLC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.